Kolon’s Osteoarthritis Gene Therapy First To Move To U.S. Phase III
This article was originally published in PharmAsia News
Invossa , a cell-mediated gene therapy for knee osteoarthritis being developed by South Korea's Kolon Group, is set to begin a Phase III clinical trial in the U.S. after receiving approval from the FDA earlier this month, and appears to be the first such therapy for the indication to progress this far.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.